Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Lexaria Bioscience Corp (NQ: LEXX ) 3.910 +0.680 (+21.05%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Lexaria Bioscience Corp < Previous 1 2 3 4 5 6 7 8 9 ... 23 24 Next > CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Extensive GLP-1 Study Program January 16, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Extensive GLP-1 Study Program January 16, 2024 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property Lexaria Unveils Extensive Planned 2024 GLP-1 Study Program January 16, 2024 Via ACCESSWIRE TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking to Grow Revenue and Commercial Opportunities Through Licensing January 12, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Lexaria's Patented Technology Improved the Oral Performance of the Rybelsus(R)-Branded GLP-1 drug Semaglutide January 04, 2024 Via ACCESSWIRE NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) Looks to Supercharge Reach, Impact of GLP-1 Agonists with Proprietary Drug-Delivery Solution January 12, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream January 11, 2024 From Lexaria Bioscience Corp. Via GlobeNewswire GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons January 10, 2024 Via Investor Brand Network GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons January 10, 2024 EQNX::TICKER_START (NASDAQ:LEXX),(NASDAQ:AMGN),(NYSE:LLY),(OTCQX:RHHBY),(NASDAQ:WW) EQNX::TICKER_END Via FinancialNewsMedia Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform January 09, 2024 From Lexaria Bioscience Corp. Via GlobeNewswire Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs January 08, 2024 Via Investor Brand Network Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs January 08, 2024 EQNX::TICKER_START (NASDAQ:LEXX),(NYSE:PFE),(NYSE:MRK),(NASDAQ:AZN),(NYSE:NVO) EQNX::TICKER_END Via FinancialNewsMedia TinyGemsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Shown to Improve Oral Performance of Rybelsus(R)-Branded GLP-1 Drug Semaglutide January 04, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Lexaria Bioscience Corp. (NASDAQ: LEXX) Provides Superior Drug and API Delivery with Patented DehydraTECH Technology December 27, 2023 Via Investor Brand Network Lexaria Bioscience Corp. (NASDAQ: LEXX) Provides Superior Drug and API Delivery with Patented DehydraTECH Technology December 27, 2023 Via CannabisNewsWire CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Leveraging Commercial Viability of DehydraTECH(TM) in Aggressive Patent Application Push December 26, 2023 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Leveraging Commercial Viability of DehydraTECH(TM) in Aggressive Patent Application Push December 26, 2023 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Lexaria Bioscience Corp. (NASDAQ: LEXX) To File its IND Application with the FDA for its planned U.S. Phase 1b Hypertension Clinical Trial December 21, 2023 Via Investor Brand Network Exposures Product Safety TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting New and More Lucrative Global Markets December 15, 2023 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes Additional Revenue Opportunities for 2024; Continues to Generate New Data for its DehydraTECH Technology December 13, 2023 Via Investor Brand Network CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Update on FDA Application for Investigational Drug December 08, 2023 Via Investor Brand Network Topics Intellectual Property Supply Chain Exposures Intellectual Property Product Safety Supply Chain CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Update on FDA Application for Investigational Drug December 08, 2023 Via CannabisNewsWire Topics Intellectual Property Supply Chain Exposures Intellectual Property Product Safety Supply Chain Lexaria's Investigational New Drug Application Filing Update December 07, 2023 Via ACCESSWIRE Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Positive Interim Results in Ongoing GLP-1 Human Pilot Study December 05, 2023 Via CannabisNewsWire Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Positive Interim Results in Ongoing GLP-1 Human Pilot Study December 05, 2023 Via Investor Brand Network Lexaria Bioscience Corp. (NASDAQ: LEXX) Building a Global Presence with Superior Delivery Technology for Wide Range of Drugs and Active Pharmaceutical Ingredients December 01, 2023 Via Investor Brand Network CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Tech Lowers Blood Glucose More Effectively than Branded GLP-1 drug Semaglutide Alone, Study Shows November 28, 2023 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Tech Lowers Blood Glucose More Effectively than Branded GLP-1 drug Semaglutide Alone, Study Shows November 28, 2023 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Lexaria's Technology Lowers Blood Glucose More Effectively than Rybelsus(R)-Branded GLP-1 drug Semaglutide Alone in Human Pilot Study November 28, 2023 Via ACCESSWIRE CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Shown to Improve Oral Performance of GLP-1 Drug in Human Pilot Study November 27, 2023 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property < Previous 1 2 3 4 5 6 7 8 9 ... 23 24 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.